Furazolidone

Overview

A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)

Indication

For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.

Associated Conditions

Diarrhea (Dysentery)
Infectious diarrhea

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment	2025/08/24	NCT07139366	Not Applicable	Not yet recruiting	Yongquan Shi
Furazolidone Quadruple Regimen Eradicate H. Pylori Infection	2025/02/12	NCT06823791	Phase 1	Completed	Liaocheng People's Hospital
The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication	2025/01/16	NCT06777732	Early Phase 1	Not yet recruiting	Nanjing First Hospital, Nanjing Medical University
Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy	2023/12/13	NCT06168084	Phase 4	Completed	Yongquan Shi
Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection	2023/02/08	NCT05718609	Phase 4	Recruiting	Second Affiliated Hospital, School of Medicine, Zhejiang University
Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin	2021/11/26	NCT05135182	Phase 4	UNKNOWN	Shandong University
Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication	2021/06/01	NCT04907747	Phase 4	UNKNOWN	Second Affiliated Hospital, School of Medicine, Zhejiang University
Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy	2020/12/22	NCT04678492	Phase 4	Completed	Xijing Hospital of Digestive Diseases
Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin	2020/02/11	NCT04264663	Phase 4	UNKNOWN	Shandong University
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication	2018/10/23	NCT03716622	Phase 4	Completed	Shandong University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
LOMOFEN Tablets	20437	Proqualix Pty Ltd - in Administration	Medicine	A	9/27/1991

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access